MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy*
- George Sgouros 1 ,
- John C. Roeske 2 ,
- Michael R. McDevitt 3 ,
- Stig Palm 4 ,
- Barry J. Allen 5 ,
- Darrell R. Fisher 6 ,
- A. Bertrand Brill 7 ,
- Hong Song 1 ,
- Roger W. Howell 8 ,
- Gamal Akabani 9 and
- In collaboration with the SNM MIRD Committee: Wesley E. Bolch, A. Bertrand Brill, Darrell R. Fisher, Roger W. Howell, Ruby F. Meredith, George Sgouros (Chair), Barry W. Wessels, and Pat B. Zanzonico
- 1Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland; 2Department of Radiation Oncology, Loyola University Medical Center, Maywood, Illinois; 3Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; 4Dosimetry and Medical Radiation Physics Section, International Atomic Energy Agency, Vienna, Austria; 5Centre for Experimental Radiation Oncology, St. George Cancer Centre, Kogarah, Australia; 6Radioisotopes Program, Pacific Northwest National Laboratory, Richland, Washington; 7Department of Radiology, Vanderbilt University, Nashville, Tennessee; 8Division of Radiation Research, Department of Radiology, New Jersey Medical School Cancer Center, University of Medicine and Dentistry of New Jersey, Newark, New Jersey; and 9Department of Nuclear Engineering, Texas A&M University, College Station, Texas
- For correspondence or reprints contact: George Sgouros, Department of Radiology and Radiological Science, CRB II 4M61/1550 Orleans St., School of Medicine, Johns Hopkins University, Baltimore, MD 21231. E-mail: gsgouros{at}jhmi.edu
Abstract
The potential of α-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of α-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with α-particle emitters. Although α-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted α-particle emitter therapy and to provide guidance and recommendations for human α-particle emitter dosimetry.
Keywords
Footnotes
-
↵* Unabridged version of this document is available at: http://interactive.snm.org/index.cfm?PageID=1110&RPID=2199&FileID=144234.
-
COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.
